Drug Trial Radar · NCT05966194
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Apr 2, 2024
Primary completion
Jul 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
Conditions
- Oral Mucositis
Interventions
RRx-001Drug
RRx-001 for injection (4 mg or 8 mg)
Intensity Modulated Radiation Therapy (IMRT)Radiation
Intensity Modulated Radiation Therapy of up to 72 Gy
Cisplatin for injection 100 mg/m2Drug
Cisplatin for injection 100 mg/m2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT)Time frame: Estimated up to 18 Months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
The University of Arizona Cancer Center
Tucson, Arizona
Miami Cancer Institute
Miami, Florida
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Parkview Cancer Institute
Fort Wayne, Indiana
Willis Knighton Cancer Center
Shreveport, Louisiana
Sandra and Malcolm Berman Cancer Institute
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Renown Regional Medical Center
Reno, Nevada
East Carolina University School of Medicine
Greenville, North Carolina
The Ohio State University James Cancer Hospital & Solove Research Institute
Columbus, Ohio
Ballad Health
Johnson City, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.